<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3088">
  <stage>Registered</stage>
  <submitdate>16/02/2011</submitdate>
  <approvaldate>16/02/2011</approvaldate>
  <nctid>NCT01304524</nctid>
  <trial_identification>
    <studytitle>A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3</studytitle>
    <scientifictitle>Phase II Placebo Controlled Study of VGX-3100, (HPV16 E6/E7, HPV18 E6/E7 DNA Vaccine) Delivered IM Followed by Electroporation With Cellectra-5P for the Treatment of Biopsy-proven CIN 2/3 or CIN 3 With Documented HPV 16 or 18.</scientifictitle>
    <utrn />
    <trialacronym>HPV-003</trialacronym>
    <secondaryid>HPV-003</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cervical Intraepithelial Neoplasia</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Cervical (cervix)</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Breast</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Other reproductive health and childbirth disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - VGX 3100
Other interventions - Placebo

Experimental: VGX 3100 - 

Placebo Comparator: Placebo - 


Other interventions: VGX 3100
1ml of VGX-3100 delivered IM followed by electroporation at Day 0, Week 4 and Week 12.

Other interventions: Placebo
1ml of placebo delivered IM followed by electroporation at Day 0, week 4 and week 12.

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Number of Participants with Histopathological Regression of Cervical Lesions to CIN 1 or Less as a Measure of Efficacy. - The number of participants with histopathologically confirmed CIN2/3 or CIN 3 associated with HPV16 or HPV18 whose cervical lesions regress to CIN 1 or less at the 36 week visit.</outcome>
      <timepoint>36 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Participants with Virologically-proven Clearance of HPV 16 or 18 in Combination with Histopathological Regression of Cervical Lesions to CIN 1 or Less as a Secondary Measure of Efficacy - The number of participants with histopathologically confirmed CIN2/3 or CIN 3 associated with HPV16 or HPV18 whose cervical lesions regress to CIN 1 or less and have virologically-proven clearance of HPV16 or HPV18 at the 36 week visit.</outcome>
      <timepoint>36 Weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Female subjects age 18-55 years;

          -  Histologically confirmed HPV-16 or HPV-18-associated CIN 2/3 or CIN 3 from tissue
             collected less than 10 weeks prior to Vaccination/EP #1 with no evidence of invasive
             cancer in any specimen;

          -  Colposcopy is satisfactory based on visualization of the entire squamocolumnar
             junction and the upper limit of the entire aceto-white or suspected CIN disease area;
             lesions in = 3 cervical quadrants (4 quadrant disease where the lesion occupies less
             than 50% of each quadrant will be considered for inclusion);

          -  Healthy subjects as judged by the Investigator based on medical history, PE, and
             normal results for an ECG, CBC, Serum Chemistries, CPK and urinalysis done up to 4
             weeks prior to enrollment and administration of study drug;

          -  Women of child-bearing potential agree to remain sexually abstinent, use two medically
             effective methods of contraception (e.g. oral contraception, barrier methods,
             spermicide, intrauterine device (IUD)), or have a partner who is sterile (i.e.,
             vasectomy) through 36 weeks (9 months);

          -  Able and willing to comply with all study procedures and voluntarily signs informed
             consent form</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Female</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Unsatisfactory colposcopy defined as incomplete visualization of the entire
             squamocolumnar junction and the upper limit of the entire aceto-white or suspected CIN
             disease area;

          -  Pregnancy or breastfeeding

          -  Immunosuppression including any concurrent condition requiring the continued use of
             systemic or topical steroids at or near the injection site [deltoid, upper arm]
             (excluding inhaled and eye drop-containing corticosteroids) or the use of
             immunosuppressive agents. All other corticosteroids must be discontinued &gt; 4 weeks
             prior to Day 0 of study vaccine administration; autoimmune disorders, transplant
             recipients;

          -  History of previous therapeutic HPV vaccination (individuals who have been immunized
             with licensed prophylactic HPV vaccines (e.g. Gardasil®, Cervarix®) are not excluded);

          -  Positive serological test for hepatitis C virus or hepatitis B virus surface
             antigen(HBsAg) or human immunodeficiency virus (HIV)

          -  Administration of any blood product within 3 months of enrollment

          -  Administration of any licensed vaccine within 2 weeks of enrollment( 4weeks for
             measles vaccine)

          -  Participation in a study with an investigational compound or device within 30 days of
             signing informed consent;

          -  Cardiac pre-excitation syndromes (such as Wolff-Parkinson-White);

          -  History of seizures (unless seizure free for 5 years);

          -  Tattoos, scars, or active lesions/rashes within 2 cm of the intended site of
             vaccination/EP or any implantable leads; or any implantable leads;

          -  Active drug or alcohol use or dependence that, in the opinion of the
             investigator,would interfere with adherence to study requirements;

          -  Prisoners or subjects who are compulsorily detained (involuntarily incarcerated)for
             treatment of either a psychiatric or physical (i.e. infections disease) illness must
             not be enrolled into this study;

          -  Any other conditions judged by the investigator that would limit the evaluation of a
             subject</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>167</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/10/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital> - Victoria</hospital>
    <postcode>3052 - Victoria</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Montana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Vancouver B.C.</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Estonia</country>
      <state>Tallinn</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Estonia</country>
      <state>Tartu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Georgia</country>
      <state>Batumi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Georgia</country>
      <state>Tbilisi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Karnataka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Rajasthan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Kolkata</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>New Delhi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Pune</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Puerto Rico</country>
      <state>San Juan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Bloemfontein</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Cape Town</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Inovio Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is randomized, placebo controlled study to determine safety and efficacy of VGX-3100 DNA
      Vaccine delivered by Electroporation to adult women with biopsy-proven HPV 16 or 18
      associated Cervical intraepithelial neoplasia grade 2/3 or 3.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01304524</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Cornelia Trimble, MD</name>
      <address>Johns Hopkins University</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>